Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Cellectis S.A. (CLLS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Cellectis S.A. (“Cellectis” or the “Company”) (NASDAQ: CLLS) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CELLECTIS S.A. (CLLS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On September 14, 2026, Cellectis announced it would prioritize in vivo gene editing therapies (HEAL-101 and HEAL-201) over CAR-T cell therapies. The Company concurrently announced it plans to discontinue the development of CAR-T cell therapies lasme-cel and eti-cel. In the accompanying conference call, the Company’s Chief Medical Officer, Adrian Kilcoyne stated “Cellectis is not able finance [Eti-cel and Lasme-cel] given the time lines that we have and the limited cash resources that we have.”
On this news, shares of Cellectis declined $1.27 per share, or 40.97%, to close at $1.83 per share on September 14, 2026, thereby injuring investors.
Contact Us To Participate or Learn More:
If you purchased Cellectis S.A. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260917556769/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?